{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:45:06Z","timestamp":1765485906948,"version":"3.48.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":323,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.101041","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:28:45Z","timestamp":1764001725000},"page":"101041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comprehensive review on outcomes from Phase 3 clinical trials of drugs in multiple myeloma"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-1270","authenticated-orcid":false,"given":"Sandeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5307-866X","authenticated-orcid":false,"given":"Vivek","family":"Uttam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2989-121X","authenticated-orcid":false,"given":"Shafiul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-0094","authenticated-orcid":false,"given":"Hardeep Singh","family":"Tuli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-2179","authenticated-orcid":false,"given":"Pallavi","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5539-3225","authenticated-orcid":false,"given":"Aklank","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ctarc.2025.101041_bib0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctarc.2025.101041_bib0002","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctarc.2025.101041_bib0003","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101041_bib0004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.ctarc.2025.101041_bib0005","article-title":"Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis","volume":"2019","author":"Piechotta","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ctarc.2025.101041_bib0006","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctarc.2025.101041_bib0007","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2025.101041_bib0008","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with Daratumumab, Lenalidomide, and Dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2025.101041_bib0009","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with Daratumumab, Bortezomib, and Dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2025.101041_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1408892","article-title":"Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4","volume":"15","author":"Hansen","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101041_bib0011","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11899-021-00624-6","article-title":"Antibody-based treatment approaches in multiple myeloma","volume":"16","author":"Hosoya","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.ctarc.2025.101041_bib0012","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ctarc.2025.101041_bib0013","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.ctarc.2025.101041_bib0014","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/10600280211058754","article-title":"Daratumumab for the treatment of Multiple myeloma: a review of clinical applicability and operational considerations","volume":"56","author":"Arnall","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"8","key":"10.1016\/j.ctarc.2025.101041_bib0015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/10600280211058754","article-title":"Daratumumab for the treatment of Multiple myeloma: a review of clinical applicability and operational considerations","volume":"56","author":"Arnall","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ctarc.2025.101041_bib0016","article-title":"Daratumumab for the management of newly diagnosed and relapsed\/refractory multiple myeloma: current and emerging treatments","volume":"10","author":"Offidani","year":"2020","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ctarc.2025.101041_bib0017","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101041_bib0018","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ctarc.2025.101041_bib0019","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"26","author":"Mateos","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2025.101041_bib0020","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.ctarc.2025.101041_bib0021","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101041_bib0022","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/bloodadvances.2023010579","article-title":"Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX","volume":"8","author":"Spencer","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.ctarc.2025.101041_bib0023","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with Daratumumab, Lenalidomide, and Dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101041_bib0024","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101041_bib0025","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s12185-021-03204-9","article-title":"Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial","volume":"114","author":"Suzuki","year":"2021","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101041_bib0026","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctarc.2025.101041_bib0027","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.ctarc.2025.101041_bib0028","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.ctarc.2025.101041_bib0029","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101041_bib0030","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2025.101041_bib0031","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.ctarc.2025.101041_bib0032","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final overall survival analysis of the TOURMALINE-MM1 Phase III trial of Ixazomib, Lenalidomide, and Dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctarc.2025.101041_bib0033","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10245","key":"10.1016\/j.ctarc.2025.101041_bib0034","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101041_bib0035","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s12185-021-03204-9","article-title":"Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial","volume":"114","author":"Suzuki","year":"2021","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101041_bib0036","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctarc.2025.101041_bib0037","first-page":"2239","article-title":"Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis","volume":"109","author":"Richardson","year":"2024","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.ctarc.2025.101041_bib0038","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101041_bib0039","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2025.101041_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1408892","article-title":"Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4","volume":"15","author":"Hansen","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101041_bib0041","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11899-021-00624-6","article-title":"Antibody-based treatment approaches in multiple myeloma","volume":"16","author":"Hosoya","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.ctarc.2025.101041_bib0042","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101041_bib0043","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101041_bib0044","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","article-title":"Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial","volume":"12","author":"Mina","year":"2025","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.ctarc.2025.101041_bib0045","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2024-0080","article-title":"Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting","volume":"13","author":"Alsdorf","year":"2024","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ctarc.2025.101041_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1424925","article-title":"Bispecific antibody targets and therapies in multiple myeloma","volume":"15","author":"Rees","year":"2024","journal-title":"Front Immunol"},{"issue":"Suppl","key":"10.1016\/j.ctarc.2025.101041_bib0047","article-title":"PB2130: magnetismm-6: a phase 3 study of Elranatamab + Daratumumab + Lenalidomide vs Daratumumab + Lenalidomide + dexamethasone in transplant ineligible patients with newly diagnosed multiple Myeloma","volume":"7","author":"Grosicki","year":"2023","journal-title":"Hemasphere"},{"issue":"Suppl","key":"10.1016\/j.ctarc.2025.101041_bib0048","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/01.HS9.0000850912.43010.d3","article-title":"PB2020: majestec-3: randomized, phase 3 study of Teclistamab plus daratumumab versus dpd or dvd in patients with relapsed\/refractory multiple myeloma","volume":"6","author":"Mateos","year":"2022","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.ctarc.2025.101041_bib0049","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.3390\/curroncol31070292","article-title":"Review of CAR T-cell therapy in multiple myeloma: a Canadian perspective","volume":"31","author":"Shih","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ctarc.2025.101041_bib0050","unstructured":"From bench to bedside: the history and progress of CAR T cell therapy - PMC [Internet]. [cited 2025 Oct 27]. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10225594\/?utm_source=chatgpt.com."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101041_bib0051","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101041_bib0052","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40364-024-00634-5","article-title":"Updates on CAR T cell therapy in multiple myeloma","volume":"12","author":"Nasiri","year":"2024","journal-title":"Biomark Res"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101041_bib0053","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2991\/chi.d.200502.001","article-title":"Maintenance strategies post-autologous stem cell transplantation for newly diagnosed multiple myeloma","volume":"2","author":"Bird","year":"2020","journal-title":"Clin Hematol Int"},{"issue":"7","key":"10.1016\/j.ctarc.2025.101041_bib0054","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41375-020-0724-1","article-title":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial","volume":"34","author":"Goldschmidt","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101041_bib0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.18600","article-title":"The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from \u201cMyeloma XI\u201d, a multicentre, open-label, randomised, phase III trial","volume":"201","author":"Jenner","year":"2023","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101041_bib0056","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","article-title":"Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE","volume":"35","author":"Goldschmidt","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2025.101041_bib0057","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/JEP.S265288","article-title":"Novel experimental drugs for treatment of multiple myeloma","volume":"13","author":"Offidani","year":"2021","journal-title":"J Exp Pharmacol"},{"issue":"10262","key":"10.1016\/j.ctarc.2025.101041_bib0058","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101041_bib0059","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ejh.14223","article-title":"Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed\/refractory multiple myeloma: extended follow-up subgroup analysis of the BOSTON trial","volume":"113","author":"Mateos","year":"2024","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.ctarc.2025.101041_bib0060","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1002\/ajh.23733","article-title":"Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma","volume":"89","author":"Ghosh","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.ctarc.2025.101041_bib0061","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-021-00490-8","article-title":"Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial","volume":"11","author":"Puig","year":"2021","journal-title":"Blood Cancer J"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:36:07Z","timestamp":1765485367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":61,"alternative-id":["S2468294225001777"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101041","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive review on outcomes from Phase 3 clinical trials of drugs in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101041"}}